Molecular Partners AG & NuMeRI, presentation Feb. 2026The Zurich-based developer is increasingly focusing its pipeline on radiopharmaceutical cancer therapies. A recent development agreement with isotope specialist Eckert & Ziegler marks another step in that direction. The collaboration aims to develop and manufacture so-called Radio-DARPin therapeutics, in which targeted protein molecules deliver radioactive isotopes directly to tumours. Early clinical data on the DARPin molecules in combination with radioisotopes suggest targeted tumour localisation. Proof of efficacy, however, is still pending.
UCB is adding a new kind of immune-cell weapon to its immunology arsenal. The Belgian biopharma said it has struck a global licensing deal with Hong Kong–based Antengene for ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) designed to deplete B cells; an approach that has long been validated in autoimmune disease, but is now being re-engineered with next-generation biologics that promise deeper, more durable effects.
French biotech OSE Immunotherapeutics is narrowing its ambitions to just two late-stage programs after a one–two hit: AbbVie backing away from an inflammation partnership and Boehringer Ingelheim halting the liver-disease leg of a separate collaboration following a mid-stage failure. The company now says it will concentrate resources on its cancer vaccine Tedopi and its IL-7 receptor antibody lusvertikimab, while pausing or ending several earlier-stage efforts to conserve cash and push toward near-term clinical catalysts.
Customized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
Courtesy Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, GermanyQuantum computers? While most people have heard that their massively parallel data processing could open up an entirely new dimension of information technology, tangible real-world examples remain scarce. NVision Imaging Technologies in Ulm has been active in the field for years and has now developed a visible and practical innovation in metabolic imaging: real-time MRI. Leading academic institutions have already expressed strong interest.